The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).
 
Shubham Pant
Consulting or Advisory Role - Celgene; Halozyme
 
Alexander I. Spira
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Byoung Chul Cho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche; Yuhan
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis
Research Funding - AstraZeneca; Bayer; Novartis; Yuhan
 
Sanjay Goel
Research Funding - Oncolytics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Prometheus; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Research Funding - Merck Sharp & Dohme
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Eisai; Roche
Speakers' Bureau - AstraZeneca
Research Funding - Acerta Pharma (Inst); ARIAD (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Biosciences (Inst); BIND Biosciences (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); United Biosource Corporation (Inst)
 
Rama Balaraman
Consulting or Advisory Role - Genentech
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Consulting or Advisory Role - Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Peleton (Inst); Pfizer (Inst); Principa Biopharma (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst)
 
Philip A. Lowry
No Relationships to Disclose
 
Ryan C. Ramaekers
No Relationships to Disclose
 
Robert D. Siegel
Research Funding - AstraZeneca (Inst); Biodesix (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Cancer Insight (Inst); Cancer Insight (Inst); CerRx (Inst); GRAIL (Inst); Immunogen (Inst); Merck (Inst); Mirati Therapeutics (Inst)
Other Relationship - American Board of Internal Medicine (ABIM)
 
Theresa Louise Werner
Research Funding - AbbVie (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche/Genentech (Inst); Tesaro (Inst)
 
Nizar M. Tannir
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Exelixis; Nektar; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
 
Demiana Faltaos
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Arena Pharma; Mirati Therapeutics
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Diane Potvin
Consulting or Advisory Role - Mirati Therapeutics
 
Saskia T.C. Neuteboom
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
James Christensen
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Bluebird Bio; Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Multiple patents in last 2 years while employed at Mirati Therapeutics covering discovery of KRAS, LSD1, and EZH2 inhibitors. (Inst)
 
Richard C. Chao
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Merck; Mirati Therapeutics; Pfizer
 
Christos Kyriakopoulos
Consulting or Advisory Role - Exelixis
Speakers' Bureau - The France Foundation
Travel, Accommodations, Expenses - Exelixis